Dr. David J. Park, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 409
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A75876
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Providence St. Jude Medical Center Fullerton, CA
Medical groups
- Providence Medical Foundation (1,466 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 409
- Services billed
- 1,584
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 663 | 282 |
| Established patient office or other outpatient visit, 40-54 minutes | 255 | 116 |
| Established patient office or other outpatient visit, 20-29 minutes | 192 | 164 |
| Insertion of needle into vein for collection of blood sample | 154 | 64 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 43 | 19 |
| New patient office or other outpatient visit, 45-59 minutes | 35 | 35 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 25 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 25 | 25 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 18 | 16 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 14 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 37 companies reported 145 payments worth $8,731 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $3,458 |
|---|---|
| Janssen Biotech, Inc. | $2,555 |
| Celgene Corporation | $269 |
| Histosonics, Inc. | $228 |
| Incyte Corporation | $183 |
| AbbVie Inc. | $175 |
| Daiichi Sankyo Inc. | $163 |
| Gilead Sciences, Inc. | $144 |
| Food and Beverage | $3,609 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $2,980 |
| Consulting Fee | $1,980 |
| Education | $138 |
| Travel and Lodging | $24.75 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $2,680 |
| Janssen Biotech, Inc. Jul 17, 2025 | Consulting Fee TECVAYLI · Oncology | $1,980 |
| AstraZeneca Pharmaceuticals LP Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) IMFINZI · Oncology Company’s descriptionSpeaker Fee | $300 |
| Incyte Corporation Apr 21, 2025 | Education | $87.99 |
| Janssen Biotech, Inc. Jun 5, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $49.99 |
| Janssen Biotech, Inc. Jun 25, 2025 | Travel and Lodging TECVAYLI · Oncology · travel to LOS ANGELES, CA · in-kind | $24.75 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 26 industry-funded studies in 2025, from 14 companies. The companies reported $827,026 in research payments for these studies, mostly to the institutions running them.
- Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Mirati Therapeutics, Inc. · Active, not recruiting · NCT05609578 - EF-44 Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure Inc. - A Phase 1 Open-label Study to Assess the Safety and Tolerability of Zolbetuximab (IMAB362) in Combination With Chemotherapy (mFOLFIRINOX) in Participants With CLDN18.2 Positive Metastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development - A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head …
Exelixis Inc. - A phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or g…
AstraZeneca Pharmaceuticals LP - A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06246916 - Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer …
Amgen Inc. - Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Mirati Therapeutics, Inc. · Active, not recruiting · NCT04793958 - A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer
AstraZeneca Pharmaceuticals LP - An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1 PD-L1 Containing Therapy HUDSON
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.